Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
UCB | Brussels | EUR | Real-time | |
UCBb | BATS Europe | EUR | Delayed | |
UCBJY | OTC Markets | USD | Delayed | |
0NZT | London | EUR | Real-time | |
UCB | TradeGate | EUR | Delayed | |
UCB | Frankfurt | EUR | Delayed | |
UCB | Vienna | EUR | Real-time |
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer’s disease; minzasolmin and UCB0222 for Parkinson’s disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Name | Age | Since | Title |
---|---|---|---|
Jan Berger | 67 | 2019 | Independent Director |
Jean-Christophe Tellier | 65 | 2014 | CEO & Executive Director |
Susan Gasser | 69 | 2021 | Independent Director |
Cyril Janssen | 53 | 2015 | Director |
Charles-Antoine Emmanuel T. Janssen | 53 | 2012 | Director |
Albrecht De Graeve | 69 | 2010 | Director |
Ulf Arne Wiinberg | 66 | 2016 | Independent Director |
Pierre L. Gurdjian | 63 | 2016 | Independent Director |
Jonkheer Cédric van Rijckevorsel | 54 | 2014 | Director |
Jonathan M. Peacock | 66 | 2021 | Independent Chair of the Board |
Alan John Blinken | - | - | Honorary Director |
Daniel Janssen | 88 | - | Honorary Deputy Chairman |
Gerhard N. Mayr | 78 | 2005 | Honorary Chairman |
Georges Jacobs de Hagen | 84 | 2005 | Honorary Chairman |
Diégo du Monceau de Bergendal | 74 | 1984 | Honorary Chairman |
Karel Boone | 81 | 2000 | Honorary Chairman |
Arnoud de Pret Roose de Calesberg | 80 | 2005 | Honorary Director |
Frederic Roch Doliveux | 68 | 2005 | Honorary Director |
Thomas Fulton Wilson McKillop | 81 | 2009 | Honorary Director |
Prince Lorenz | - | 2001 | Honorary Director |
Peter J. Fellner | 81 | 2005 | Honorary Director |
Norman J. Ornstein | 76 | 2008 | Honorary Director |
Guy Keutgen | - | 1990 | Honorary Director |
Mark Eyskens | - | 2005 | Honorary Chairman |
Jean-Pierre Kinet | 71 | 2008 | Honorary Director |
Gaëtan van de Werve | - | 2006 | Honorary Director |
Jean van Rijckevorsel | - | 1992 | Honorary Director |
Jean-Louis Vanherweghem | - | - | Honorary Director |
Alice Dautry | 74 | 2015 | Honorary Director |
Dame Kay Davies | 73 | 2014 | Independent Director |
Maelys Castella | 58 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review